Context Several recent phase 2 and 3 trials have evaluated the efficacy and toxicity of
checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized …

ABSTRACT Background and Objective The Surveillance, Epidemiology, and End Results
Program (SEER) program and the National Program of Cancer Registries (NPCR), are …

With the rapidly increasing incidence of bladder cancer in China and worldwide, great efforts
have been made to understand the detailed mechanism of bladder cancer tumorigenesis …

Background Cisplatin (CDDP) has become a standard-of-care treatment for muscle-invasive
bladder cancer (MIBC), while chemoresistance remains a major challenge. Accumulating …

Importance Immune checkpoint inhibitors (ICIs) are part of standard of care for patients with
many advanced solid tumors. Patients with poor performance status or organ dysfunction …

Importance Although digital cognitive behavioral therapy for insomnia (dCBT-I) has been
studied in many randomized clinical trials and is recommended as a first-line treatment …

Importance Prospective evidence suggests abiraterone is associated with superior
progression-free survival for African American men compared with non-Hispanic White men …

Background In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to
predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical …

Insulin-like growth factor binding protein-7 (IGFBP7) was recently reported to be a ligand of
CD93, a potential target to normalize vasculature and attenuate immunotherapy. However …

PURPOSE In real-world settings, patients with metastatic urothelial carcinoma (mUC) are
often more frail than clinical trials, underscoring an unmet need to identify patients who …